A study to investigate the bioavailability of the SAR444656 test formulation and the food effect on the SAR444656 test formulation in healthy adult participants

2024-515621-28-00 Protocol BDR17530 Human pharmacology (Phase I) - Other Ended

Start 17 Apr 2025 · End 24 Jun 2025 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol BDR17530

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ended
Participants planned 80
Countries 1
Sites 1

Healthy Volunteer

Key facts

Sponsor
Sanofi-Aventis Recherche & Developpement
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Diseases [C] - Immune System Diseases [C20]
Trial duration
17 Apr 2025 → 24 Jun 2025
Decision date (initial)
2025-03-25
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-515621-28-00
WHO UTN
U1111-1307-7447

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Healthy Volunteer

VersionLevelCodeTermSystem organ class
26.0 LLT 10088820 Clinical trial healthy volunteer 100000004848

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Sanofi-Aventis Recherche & Developpement

Sponsor organisation
Sanofi-Aventis Recherche & Developpement
Address
82 Avenue Raspail
City
Gentilly
Postcode
94250
Country
France

Scientific contact point

Organisation
Sanofi-Aventis Recherche & Developpement
Contact name
Clinical Sciences and Operations

Public contact point

Organisation
Sanofi-Aventis Recherche & Developpement
Contact name
Clinical Sciences and Operations

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Belgium Ended 80 1
Rest of world 0

Investigational sites

Belgium

1 site · Ended
SGS Belgium
SGS-Clinical Research CPU, Drie Eikenstraat 655, 2650, Edegem

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Belgium 2025-04-17 2025-04-17 2025-06-24

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-02-19 Belgium Acceptable
2025-03-25
2025-03-25
2 NON SUBSTANTIAL MODIFICATION NSM-1 2025-06-30 Belgium Acceptable
2025-03-25
2025-06-30